[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622616":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":37,"responsibleParty":51,"collaborators":25,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":25,"enrollmentInfo":64,"targetDuration":25,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":79,"whyStopped":25,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Universidad Católica San Antonio de Murcia","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo","PLACEBO_COMPARATOR","The product will have the same characteristics as the experimental product.",[13],"Dietary Supplement: Control product placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"Genistein","EXPERIMENTAL","Subjects will consume two capsules daily. Each capsule will be taken before the two main meals, each 100 mg tablet.",[19],"Dietary Supplement: Genistein",[21,26],{"type":22,"name":15,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","Soy isoflavone",[15],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Control product placebo","It will be supplied in a color and shape similar to the active product, but with maltodextrin, an inert substance.",[9],[31],{"name":32,"role":33,"phone":34,"phoneExt":35,"email":36},"Francisco Javier López Román","CONTACT","968278157","157","jlroman@ucam.edu",[38],{"facility":39,"status":25,"city":40,"state":25,"zip":25,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"UCAM HiTech, Sport & Health Innovation Hub","Murcia","Spain","ES",{"type":44,"coordinates":45},"Point",[46,47],-1.13004,37.98704,{"lat":47,"lon":46},[50],{"name":32,"role":33,"phone":34,"phoneExt":35,"email":36},{"type":52,"investigatorFullName":32,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Principal Investigator","100622616","effectiveness-of-genistein-in-mild-cognitive-impairment-100622616",false,"NCT07385937","Effectiveness of Genistein in Mild Cognitive Impairment","Effectiveness of Genistein on the Progression of Cognitive Impairment in Patients With Mild Cognitive Impairment: Controlled Clinical Trial","EXTRAGENIAL","Inclusion Criteria:\n\n* Patient over 50 years of age.\n* Patient diagnosed with mild cognitive impairment (MCI) for Alzheimer's disease (AD) according to the National Institute on Aging and Alzheimer's Association (NIA-AA, 2024) criteria:\n\n  * MMSE scores between 22 and 30 (inclusive; exceptions may be made for subjects with less than 5 years of education).\n  * Evidence of concern about change in cognition, compared to the person's previous level (subjective memory complaint\u002Fimpairment for more than 6 months in the past year and\u002For confirmed by the informant and\u002For physician).\n  * A Clinical Dementia Rating (CDR) score of 0.5 with a memory domain score of 0.5.\n  * Essentially preserved activities of daily living.\n* Evidence of elevated cortical amyloid by positron emission tomography (PET) with F18-flutemetamol. • Patients will be treated pharmaceutically according to the guidelines.\n\nExclusion Criteria:\n\n* Diagnosis of a significant neurological disease other than Alzheimer's disease.\n* Moderate depression as assessed by a Geriatric Depression Scale (GDS-D) score \\>8, or any other serious psychiatric disorder.\n* Taking supplements containing isoflavones.\n* Having a hormone-dependent neoplastic disease.\n* Diagnosis of significant cerebrovascular disease.\n* Having a serious systemic illness that would prevent completion of the study.","ALL","50 Years",{"count":65,"type":66},150,"ESTIMATED","INTERVENTIONAL",[69],"NA","Randomized, placebo-controlled, double-blind, multicenter clinical trial with two parallel study arms (experimental and placebo) to assess the efficacy of genistein extract consumption over 18 months on cognitive decline in patients with prodromal Alzheimer's disease.",[72,73],"Alzheimer Disease (AD)","Mild Cognitive Impairment (MCI)",[15,75,76,77,78],"Dementia","Cognitive impairment","Neuroprotection","Prevention","NOT_YET_RECRUITING","2026-02-12",{"date":82,"type":83},"2026-02-17","ACTUAL",{"date":85,"type":66},"2026-02",{"date":87,"type":66},"2027-12",{"name":5,"class":6},1]